After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more_老虎社区_美港股上老虎

After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more

StreetInsider2021-12-21

After-Hours Stock Movers: Micron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

338

Cockatoo
·2021-12-21
🧐$Micron Technology(MU)$
回复
3
举报
Jialatsia
·2021-12-21
Meep
回复
2
举报
收起
- Cockatoo:
  💵
  2021-12-21
  回复
  举报
Gladys8jk
·2021-12-21
Ok
回复
1
举报
MuppyKoh
·2021-12-21
Please like
回复
3
举报
收起
- SeL:
  Ok
  2021-12-21
  回复
  举报
Zhen95
·2021-12-21
Like and comment
回复
3
举报
收起
- Zhen95:
  ok
  2021-12-21
  回复
  举报
- PickleT68:
  Done
  2021-12-21
  回复
  举报
Arnoldy
·2021-12-21
Like
回复
4
举报
收起
- Zhen95:
  ok
  2021-12-21
  回复
  举报
- calebxiong:
  ok
  2021-12-21
  回复
  举报
ew1202
·2021-12-21
Go micron
回复
3
举报
JLBW
·2021-12-21
Pls like
回复
7
举报
DSYH
·2021-12-21
Like pls
回复
5
举报
ChrisLiew
·2021-12-21
Like and comment pls
回复
4
举报
收起
- FreebigmoNeY:
  Ok
  2021-12-21
  回复
  举报
- JLBW:
  Ok
  2021-12-21
  回复
  举报
- Kaden0204:
  ok
  2021-12-21
  回复
  举报
HumjimPiang8
·2021-12-21
thanks for sharing
回复
3
举报
收起
- DSYH:
  ok
  2021-12-21
  回复
  举报
- ChrisLiew:
  [Cool]
  2021-12-21
  回复
  举报
Natlow
·2021-12-21
Ok
回复
3
举报
收起
- gsz:
  ok
  2021-12-21
  回复
  举报
- Natlow:
  ok
  2021-12-21
  回复
  举报
cassan
·2021-12-21
Pls like
回复
7
举报
收起
- ZachLoh:
  K
  2021-12-21
  回复
  举报
Don3
·2021-12-21
Please like
回复
6
举报
收起
- cassan:
  Ok
  2021-12-21
  回复
  举报
Kc48
·2021-12-21
Like pls
回复
4
举报
收起
- Don3:
  ok
  2021-12-21
  回复
  举报
Kc48
·2021-12-21
Ok
回复
1
举报
收起
- Kc48:
  Ok
  2021-12-21
  回复
  举报
525d868
·2021-12-21
Like and comment thanks
回复
6
举报
收起
- 525d868:
  Thanks!
  2021-12-21
  回复
  举报
- 525d868:
  [Smile][Smile][Smile]
  2021-12-21
  回复
  举报
- 525d868:
  [Great]
  2021-12-21
  回复
  举报
查看更多 2 条评论
jack_paing
·2021-12-21
like
回复
3
举报
收起
- 525d868:
  O
  2021-12-21
  回复
  举报
1nu
·2021-12-21
Help me like and comment:)
回复
9
举报
收起
- JenneyJJ:
  Done, pls like and comment in return. Thanks
  2021-12-21
  回复
  举报
- jack_paing:
  ok
  2021-12-21
  回复
  举报
- phtan68:
  liked
  2021-12-21
  回复
  举报
查看更多 1 条评论
FinFree
·2021-12-21
Ok
回复
4
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1102941409?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-21 07:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102941409","market":"us","top_or_hot":-1,"title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","media":"StreetInsider","content":"<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">网页链接</a>\n\n</div>\n","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALDX","symbol_name":"Aldeyra Therapeutics Inc","start_time":0,"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","article_id":"1102941409","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","pubTimestamp":1640044036,"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","MU":"美光科技","SOPA":"Society Pass Inc","NKE":"耐克"},"translate_title":"下班后股票搬运工：美光、耐克、Aldeyra Therapeutics等","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALDX":0.9,"MU":0.9,"NKE":0.9,"SOPA":0.9},"content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[{"id":693571191,"gmtCreate":1640054488738,"gmtModify":1640055057430,"author":{"id":"4095668241594670","authorId":"4095668241594670","name":"Cockatoo","avatar":"https://static.tigerbbs.com/0055bde0938dcc9ff3f3925ff22ea2c7","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"🧐<a href=\"https://laohu8.com/S/MU\">$Micron Technology(MU)$</a>","listText":"🧐<a href=\"https://laohu8.com/S/MU\">$Micron Technology(MU)$</a>","text":"🧐$Micron Technology(MU)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693571191","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","pubTimestamp":1640044036,"share":"https://www.laohu8.com/m/news/1102941409?lang=&edition=full","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc","ALDX":"Aldeyra Therapeutics Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":693568636,"gmtCreate":1640050916126,"gmtModify":1640050969181,"author":{"id":"4087959350378170","authorId":"4087959350378170","name":"Jialatsia","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"Meep","listText":"Meep","text":"Meep","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693568636","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","pubTimestamp":1640044036,"share":"https://www.laohu8.com/m/news/1102941409?lang=&edition=full","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc","ALDX":"Aldeyra Therapeutics Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7062636,"gmtCreate":1640054501473,"gmtModify":1640054501571,"authorId":4095668241594670,"author":{"id":4095668241594670,"authorId":4095668241594670,"name":"Cockatoo","avatar":"https://static.tigerbbs.com/0055bde0938dcc9ff3f3925ff22ea2c7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693568636,"type":1,"supId":0,"prevId":0,"content":"💵","text":"💵","html":"💵"}],"langContent":"CN"},{"id":693561748,"gmtCreate":1640050880980,"gmtModify":1640050881395,"author":{"id":"4094787128284850","authorId":"4094787128284850","name":"Gladys8jk","avatar":"https://static.tigerbbs.com/789bbf473867763cd44be080e269826d","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693561748","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","pubTimestamp":1640044036,"share":"https://www.laohu8.com/m/news/1102941409?lang=&edition=full","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc","ALDX":"Aldeyra Therapeutics Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":693532834,"gmtCreate":1640048465150,"gmtModify":1640048465606,"author":{"id":"3585354270249282","authorId":"3585354270249282","name":"MuppyKoh","avatar":"https://static.tigerbbs.com/280b63f52e5976fb134c31bfb22ec07d","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Please like","listText":"Please like","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693532834","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","pubTimestamp":1640044036,"share":"https://www.laohu8.com/m/news/1102941409?lang=&edition=full","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc","ALDX":"Aldeyra Therapeutics Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7061936,"gmtCreate":1640050848432,"gmtModify":1640050848466,"authorId":3583197598199652,"author":{"id":3583197598199652,"authorId":3583197598199652,"name":"SeL","avatar":"https://static.tigerbbs.com/ad7f9d9a13a537bcb9c5ad29a65aa424","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693532834,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":693532922,"gmtCreate":1640048443673,"gmtModify":1640048444327,"author":{"id":"3575252907553393","authorId":"3575252907553393","name":"Zhen95","avatar":"https://static.tigerbbs.com/62a4767b8928f124a0f7f02bd3c21f62","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/693532922","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","pubTimestamp":1640044036,"share":"https://www.laohu8.com/m/news/1102941409?lang=&edition=full","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc","ALDX":"Aldeyra Therapeutics Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7065743,"gmtCreate":1640082222611,"gmtModify":1640082222645,"authorId":3575252907553393,"author":{"id":3575252907553393,"authorId":3575252907553393,"name":"Zhen95","avatar":"https://static.tigerbbs.com/62a4767b8928f124a0f7f02bd3c21f62","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693532922,"type":1,"supId":7061809,"prevId":0,"content":"ok","text":"ok","html":"ok"},{"id":7061809,"gmtCreate":1640050342286,"gmtModify":1640050342323,"authorId":3581915827887523,"author":{"id":3581915827887523,"authorId":3581915827887523,"name":"PickleT68","avatar":"https://static.tigerbbs.com/8fce28b8d12bdeb2997c5098f8b8e413","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693532922,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"CN"},{"id":693536458,"gmtCreate":1640048431502,"gmtModify":1640048431757,"author":{"id":"3577504972179170","authorId":"3577504972179170","name":"Arnoldy","avatar":"https://static.tigerbbs.com/3bfdb559c890249bf261380cb2bd5721","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/693536458","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","pubTimestamp":1640044036,"share":"https://www.laohu8.com/m/news/1102941409?lang=&edition=full","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc","ALDX":"Aldeyra Therapeutics Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7061350,"gmtCreate":1640048453216,"gmtModify":1640048453313,"authorId":3575252907553393,"author":{"id":3575252907553393,"authorId":3575252907553393,"name":"Zhen95","avatar":"https://static.tigerbbs.com/62a4767b8928f124a0f7f02bd3c21f62","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693536458,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"},{"id":7061348,"gmtCreate":1640048451355,"gmtModify":1640048451388,"authorId":3573369466096628,"author":{"id":3573369466096628,"authorId":3573369466096628,"name":"calebxiong","avatar":"https://static.tigerbbs.com/08d48582a3126a51d85cbec3a72f9923","vip":1,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693536458,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"},{"id":693536148,"gmtCreate":1640048395206,"gmtModify":1640048395287,"author":{"id":"3577091643764482","authorId":"3577091643764482","name":"ew1202","avatar":"https://static.tigerbbs.com/39fd4df438885b50c79f4ae10e1a8ed0","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Go micron","listText":"Go micron","text":"Go micron","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693536148","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","pubTimestamp":1640044036,"share":"https://www.laohu8.com/m/news/1102941409?lang=&edition=full","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc","ALDX":"Aldeyra Therapeutics Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":693536975,"gmtCreate":1640048371905,"gmtModify":1640048372103,"author":{"id":"4088639231266520","authorId":"4088639231266520","name":"JLBW","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693536975","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","pubTimestamp":1640044036,"share":"https://www.laohu8.com/m/news/1102941409?lang=&edition=full","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc","ALDX":"Aldeyra Therapeutics Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":693536059,"gmtCreate":1640048367608,"gmtModify":1640048367995,"author":{"id":"3576529744197419","authorId":"3576529744197419","name":"DSYH","avatar":"https://static.tigerbbs.com/1b1ab721d954c8f8215155b381c73f72","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693536059","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","pubTimestamp":1640044036,"share":"https://www.laohu8.com/m/news/1102941409?lang=&edition=full","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc","ALDX":"Aldeyra Therapeutics Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":693538545,"gmtCreate":1640048347618,"gmtModify":1640048347865,"author":{"id":"3580393689769738","authorId":"3580393689769738","name":"ChrisLiew","avatar":"https://static.tigerbbs.com/35b3b9b772013ce79f9f4c5318d46fa7","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like and comment pls","listText":"Like and comment pls","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/693538545","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","pubTimestamp":1640044036,"share":"https://www.laohu8.com/m/news/1102941409?lang=&edition=full","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc","ALDX":"Aldeyra Therapeutics Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7061343,"gmtCreate":1640048440905,"gmtModify":1640048440938,"authorId":3578472903237510,"author":{"id":3578472903237510,"authorId":3578472903237510,"name":"FreebigmoNeY","avatar":"https://static.tigerbbs.com/3a31b93448657f6d83ec000012f9f9e6","vip":1,"crmLevel":8,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693538545,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":7061331,"gmtCreate":1640048387483,"gmtModify":1640048387513,"authorId":4088639231266520,"author":{"id":4088639231266520,"authorId":4088639231266520,"name":"JLBW","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693538545,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":7061327,"gmtCreate":1640048360114,"gmtModify":1640048360150,"authorId":4097384260129050,"author":{"id":4097384260129050,"authorId":4097384260129050,"name":"Kaden0204","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693538545,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"},{"id":693538233,"gmtCreate":1640048344429,"gmtModify":1640048344562,"author":{"id":"3555385471829073","authorId":"3555385471829073","name":"HumjimPiang8","avatar":"https://static.tigerbbs.com/f7ab83fa2cfc43af0bc458b43eca1ebb","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"thanks for sharing","listText":"thanks for sharing","text":"thanks for sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/693538233","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","pubTimestamp":1640044036,"share":"https://www.laohu8.com/m/news/1102941409?lang=&edition=full","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc","ALDX":"Aldeyra Therapeutics Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7061329,"gmtCreate":1640048375282,"gmtModify":1640048375316,"authorId":3576529744197419,"author":{"id":3576529744197419,"authorId":3576529744197419,"name":"DSYH","avatar":"https://static.tigerbbs.com/1b1ab721d954c8f8215155b381c73f72","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693538233,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"},{"id":7061328,"gmtCreate":1640048370885,"gmtModify":1640048370917,"authorId":3580393689769738,"author":{"id":3580393689769738,"authorId":3580393689769738,"name":"ChrisLiew","avatar":"https://static.tigerbbs.com/35b3b9b772013ce79f9f4c5318d46fa7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693538233,"type":1,"supId":0,"prevId":0,"content":"[Cool]","text":"[Cool]","html":"[Cool]"}],"langContent":"CN"},{"id":693538812,"gmtCreate":1640048309499,"gmtModify":1640048309835,"author":{"id":"3580161027656510","authorId":"3580161027656510","name":"Natlow","avatar":"https://static.tigerbbs.com/14a777947812993c0fa2085832de2e68","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/693538812","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","pubTimestamp":1640044036,"share":"https://www.laohu8.com/m/news/1102941409?lang=&edition=full","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc","ALDX":"Aldeyra Therapeutics Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7061323,"gmtCreate":1640048349297,"gmtModify":1640048349400,"authorId":3568243121821953,"author":{"id":3568243121821953,"authorId":3568243121821953,"name":"gsz","avatar":"https://static.tigerbbs.com/9d9d2a871f9324a5f8055fe44ab9b8b5","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693538812,"type":1,"supId":7061319,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"},{"id":7061319,"gmtCreate":1640048315670,"gmtModify":1640048315697,"authorId":3580161027656510,"author":{"id":3580161027656510,"authorId":3580161027656510,"name":"Natlow","avatar":"https://static.tigerbbs.com/14a777947812993c0fa2085832de2e68","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693538812,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"},{"id":693538024,"gmtCreate":1640048292932,"gmtModify":1640048293243,"author":{"id":"3562891229203554","authorId":"3562891229203554","name":"cassan","avatar":"https://static.tigerbbs.com/2f12a58ed338611b5e581e7f21ac579b","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693538024","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","pubTimestamp":1640044036,"share":"https://www.laohu8.com/m/news/1102941409?lang=&edition=full","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc","ALDX":"Aldeyra Therapeutics Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7061316,"gmtCreate":1640048299973,"gmtModify":1640048300075,"authorId":3569225668665653,"author":{"id":3569225668665653,"authorId":3569225668665653,"name":"ZachLoh","avatar":"https://static.tigerbbs.com/39ae35b0a4b7e22dee7378b1bc1de2f6","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693538024,"type":1,"supId":0,"prevId":0,"content":"K","text":"K","html":"K"}],"langContent":"CN"},{"id":693531652,"gmtCreate":1640048246523,"gmtModify":1640048246794,"author":{"id":"3581937274949753","authorId":"3581937274949753","name":"Don3","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Please like","listText":"Please like","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693531652","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","pubTimestamp":1640044036,"share":"https://www.laohu8.com/m/news/1102941409?lang=&edition=full","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc","ALDX":"Aldeyra Therapeutics Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7061313,"gmtCreate":1640048284035,"gmtModify":1640048284067,"authorId":3562891229203554,"author":{"id":3562891229203554,"authorId":3562891229203554,"name":"cassan","avatar":"https://static.tigerbbs.com/2f12a58ed338611b5e581e7f21ac579b","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693531652,"type":1,"supId":0,"prevId":0,"content":"<u>Ok</u>","text":"<u>Ok</u>","html":"<u>Ok</u>"}],"langContent":"CN"},{"id":693531860,"gmtCreate":1640048234801,"gmtModify":1640048235238,"author":{"id":"3582943967323128","authorId":"3582943967323128","name":"Kc48","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693531860","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","pubTimestamp":1640044036,"share":"https://www.laohu8.com/m/news/1102941409?lang=&edition=full","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc","ALDX":"Aldeyra Therapeutics Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7061307,"gmtCreate":1640048255144,"gmtModify":1640048255174,"authorId":3581937274949753,"author":{"id":3581937274949753,"authorId":3581937274949753,"name":"Don3","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693531860,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"},{"id":693531382,"gmtCreate":1640048224141,"gmtModify":1640048224603,"author":{"id":"3582943967323128","authorId":"3582943967323128","name":"Kc48","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693531382","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","pubTimestamp":1640044036,"share":"https://www.laohu8.com/m/news/1102941409?lang=&edition=full","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc","ALDX":"Aldeyra Therapeutics Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7061326,"gmtCreate":1640048356513,"gmtModify":1640048356600,"authorId":3582943967323128,"author":{"id":3582943967323128,"authorId":3582943967323128,"name":"Kc48","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693531382,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":693533549,"gmtCreate":1640048125418,"gmtModify":1640063047373,"author":{"id":"3586053409735009","authorId":"3586053409735009","name":"525d868","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like and comment thanks&nbsp;","listText":"Like and comment thanks&nbsp;","text":"Like and comment thanks","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":6,"commentSize":10,"repostSize":0,"link":"https://laohu8.com/post/693533549","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","pubTimestamp":1640044036,"share":"https://www.laohu8.com/m/news/1102941409?lang=&edition=full","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc","ALDX":"Aldeyra Therapeutics Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7063853,"gmtCreate":1640063047329,"gmtModify":1640063047454,"authorId":3586053409735009,"author":{"id":3586053409735009,"authorId":3586053409735009,"name":"525d868","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693533549,"type":1,"supId":7063844,"prevId":0,"content":"Thanks! ","text":"Thanks! ","html":"Thanks! "},{"id":7063852,"gmtCreate":1640063040809,"gmtModify":1640063040839,"authorId":3586053409735009,"author":{"id":3586053409735009,"authorId":3586053409735009,"name":"525d868","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693533549,"type":1,"supId":7063844,"prevId":0,"content":"[Smile][Smile][Smile]","text":"[Smile][Smile][Smile]","html":"[Smile][Smile][Smile]"},{"id":7063851,"gmtCreate":1640063033058,"gmtModify":1640063033143,"authorId":3586053409735009,"author":{"id":3586053409735009,"authorId":3586053409735009,"name":"525d868","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693533549,"type":1,"supId":7063844,"prevId":0,"content":"[Great]","text":"[Great]","html":"[Great]"},{"id":7063850,"gmtCreate":1640063022570,"gmtModify":1640063022658,"authorId":3586053409735009,"author":{"id":3586053409735009,"authorId":3586053409735009,"name":"525d868","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693533549,"type":1,"supId":7063844,"prevId":0,"content":"[What]","text":"[What]","html":"[What]"},{"id":7063847,"gmtCreate":1640063016080,"gmtModify":1640063016111,"authorId":3586053409735009,"author":{"id":3586053409735009,"authorId":3586053409735009,"name":"525d868","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693533549,"type":1,"supId":7063844,"prevId":0,"content":"[Happy]","text":"[Happy]","html":"[Happy]"}],"langContent":"CN"},{"id":693533673,"gmtCreate":1640048107789,"gmtModify":1640048107939,"author":{"id":"3581833173571708","authorId":"3581833173571708","name":"jack_paing","avatar":"https://static.tigerbbs.com/3eb267d3238b5dcb9bfb6ceb846015c7","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693533673","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","pubTimestamp":1640044036,"share":"https://www.laohu8.com/m/news/1102941409?lang=&edition=full","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc","ALDX":"Aldeyra Therapeutics Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7061276,"gmtCreate":1640048132456,"gmtModify":1640048132564,"authorId":3586053409735009,"author":{"id":3586053409735009,"authorId":3586053409735009,"name":"525d868","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693533673,"type":1,"supId":0,"prevId":0,"content":"O","text":"O","html":"O"}],"langContent":"CN"},{"id":693539047,"gmtCreate":1640047959243,"gmtModify":1640047959702,"author":{"id":"3577610430427001","authorId":"3577610430427001","name":"1nu","avatar":"https://static.tigerbbs.com/15789a74f3eb14371af59c44a8f71041","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Help me like and comment:)","listText":"Help me like and comment:)","text":"Help me like and comment:)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/693539047","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","pubTimestamp":1640044036,"share":"https://www.laohu8.com/m/news/1102941409?lang=&edition=full","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc","ALDX":"Aldeyra Therapeutics Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7061295,"gmtCreate":1640048194840,"gmtModify":1640048194932,"authorId":3573203718015318,"author":{"id":3573203718015318,"authorId":3573203718015318,"name":"JenneyJJ","avatar":"https://static.tigerbbs.com/8886c72f606e31ed1eacbf1e0fb36fef","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693539047,"type":1,"supId":0,"prevId":0,"content":"Done, pls like and comment in return. Thanks","text":"Done, pls like and comment in return. Thanks","html":"Done, pls like and comment in return. Thanks"},{"id":7061269,"gmtCreate":1640048113411,"gmtModify":1640048113442,"authorId":3581833173571708,"author":{"id":3581833173571708,"authorId":3581833173571708,"name":"jack_paing","avatar":"https://static.tigerbbs.com/3eb267d3238b5dcb9bfb6ceb846015c7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693539047,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"},{"id":7061234,"gmtCreate":1640048001534,"gmtModify":1640048001572,"authorId":3574739732742262,"author":{"id":3574739732742262,"authorId":3574739732742262,"name":"phtan68","avatar":"https://static.tigerbbs.com/6e3f25ca6f0628d3425ae8bb0e944aab","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693539047,"type":1,"supId":7061230,"prevId":0,"content":"liked","text":"liked","html":"liked"},{"id":7061230,"gmtCreate":1640047989869,"gmtModify":1640047989903,"authorId":3586842860544589,"author":{"id":3586842860544589,"authorId":3586842860544589,"name":"sjfoo0108","avatar":"https://static.tigerbbs.com/58fb2fc0bc203e30e119c9756c22ca34","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693539047,"type":1,"supId":0,"prevId":0,"content":"liked","text":"liked","html":"liked"}],"langContent":"CN"},{"id":693530480,"gmtCreate":1640047938746,"gmtModify":1640047939021,"author":{"id":"3575427961987459","authorId":"3575427961987459","name":"FinFree","avatar":"https://static.tigerbbs.com/c9b0cb07fc0f99b802cfb85b3a20b578","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693530480","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","pubTimestamp":1640044036,"share":"https://www.laohu8.com/m/news/1102941409?lang=&edition=full","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc","ALDX":"Aldeyra Therapeutics Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":338,"commentSize":0,"repostSize":0,"favoriteSize":2,"likeStatus":false,"favoriteStatus":false}}